Raymond James Upgrades Immunovant to Outperform, Announces $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has upgraded Immunovant (NASDAQ:IMVT) from Market Perform to Outperform and set a price target of $40.
September 27, 2023 | 8:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunovant's stock has been upgraded to Outperform by Raymond James with a price target of $40.
The upgrade from Raymond James is a positive signal for Immunovant. The new rating of Outperform suggests that the analyst believes the company will outperform the market, which could lead to an increase in the stock price. The price target of $40 also indicates a positive outlook for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100